Results 221 to 230 of about 29,053 (244)
Some of the next articles are maybe not open access.
Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals, 2013Radionuclide therapy (RNT) based on the concept of delivering cytotoxic levels of radiation to disease sites is one of the rapidly growing fields of nuclear medicine. Unlike conventional external beam therapy, RNT targets diseases at the cellular level rather than on a gross anatomical level.
M. R. A. Pillai +2 more
openaire +3 more sources
2009
Most patients with advanced cancer develop metastatic bone disease; this untreatable evolution of the disease weights heavily on cancer-related mortality and morbidity. Although bone metastases are often clinically silent, some conditions may support bone pain.
openaire +1 more source
Most patients with advanced cancer develop metastatic bone disease; this untreatable evolution of the disease weights heavily on cancer-related mortality and morbidity. Although bone metastases are often clinically silent, some conditions may support bone pain.
openaire +1 more source
Clinical Radionuclide Therapy [PDF]
, 2008 Clinical applications of targeted radionuclide treatment have evolved considerably over the last 10–20 years, principally as a result of an improved understanding of tumour biology, and the identification of biochemical pathways and protein targets expressed preferentially on tumours compared to normal tissue.
Andrew M. Scott +3 more
openaire +1 more source
Radionuclides and carrier molecules for therapy [PDF]
Physics in Medicine and Biology, 1996 Although radionuclide therapy has been around for a long time, this modality of cancer treatment has been limited mainly to the use of [32P]-phosphate and [131I]-sodium iodide. The last few years, however, have seen an increased interest in this area due to new developments of radionuclides and carrier molecules that may provide selective targeting of ...
openaire +2 more sources
Radionuclide Therapy in Melanoma
2012Melanoma is being diagnosed more often than ever before. This may be due in part to greater vigilance but there is, nevertheless, a steadily increasing incidence of the disease in the western world. Melanoma accounts for less than 5 % of skin cancers but is the cause of more than 80 % of deaths from skin cancer, and the loss of life years is amplified ...
Robert Howman-Giles +2 more
openaire +2 more sources
Radionuclide Therapy of Leukemias [PDF]
, 2012 Leukemia is currently the most common fatal cancer in the United States among males younger than 40 years old, whereas bronchopulmonary cancer predominates in men aged 40 years and older. Among females, leukemia is the leading cause of cancer death before age 20 years, breast cancer ranks first at ages 20–59 years, and lung cancer ranks first at ages ...
openaire +1 more source
The use of radionuclides for tumor therapy
International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1986The successful use of radionuclides for tumor therapy depends to a major extent on the ability to achieve a high concentration of radioactivity in the tumor relative to other radiosensitive organs not involved by tumor, such as bone marrow, intestinal mucosa, liver, and kidneys.
Rashid A. Fawwaz +3 more
openaire +3 more sources
Radionuclide therapy beyond radioiodine
Wiener Medizinische Wochenschrift, 2012For decades, Iodine-131 has been used for the treatment of patients with thyroid cancer. In recent years, increasingly, other radiopharmaceuticals are in clinical use in the treatment of various malignant diseases. Although in principle these therapies-as in all applications of radionuclides-special radiation protection measures are required, a ...
openaire +3 more sources
Radionuclide therapy of adrenal tumors
Journal of Surgical Oncology, 2012AbstractAdrenal tumors arising from chromaffin cells will often accumulate radiolabeled metaiodobenzylguanidine (MIBG) and thus are amenable to therapy with I‐131 MIBG. More recently, therapy studies have targeted the somatostatin receptors using Lu‐177 or Y‐90 radiolabeled somatostatin analogs.
Jorge A. Carrasquillo +2 more
openaire +3 more sources
Beta-Emitting Radionuclides for Peptide Receptor Radionuclide Therapy
Current Topics in Medicinal Chemistry, 2013The paper focuses on the β-emitting radionuclides which might be useful for peptide receptor radionuclide therapy, PRRT. For the effective design of the radiopharmaceutical, the choice of radionuclide will depend on the purpose for which the radioligand is being used and on the physicochemical properties of the radionuclide.
Parus Jl, Mikolajczak R
openaire +3 more sources